- Report
- December 2023
- 143 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- June 2021
- 102 Pages
Global
€20914EUR$22,000USD£17,570GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4706EUR$4,950USD£3,953GBP
- Report
- February 2024
- 115 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- March 2023
- 209 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- August 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- October 2022
- 182 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- July 2023
- 128 Pages
North America
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2023
- 139 Pages
Europe
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2023
- 141 Pages
Asia Pacific
From €1426EUR$1,500USD£1,198GBP
- Report
- July 2023
- 142 Pages
Africa, Middle East
From €1426EUR$1,500USD£1,198GBP
- Report
- October 2022
- 232 Pages
Global
From €3422EUR$3,600USD£2,875GBP
- Report
- October 2022
- 79 Pages
North America
From €1426EUR$1,500USD£1,198GBP
- Report
- February 2024
- 37 Pages
Global
From €9502EUR$9,995USD£7,982GBP
- Report
- May 2022
- 196 Pages
Global
€4161EUR$4,377USD£3,496GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- February 2024
- 112 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- October 2024
- 260 Pages
Global
From €2524EUR$2,655USD£2,120GBP
- Report
- May 2023
- 458 Pages
Global
From €3394EUR$3,570USD£2,851GBP

In the field of hematology, Hemophilia B, also known as Christmas disease, is a genetic disorder characterized by insufficient blood clotting due to the absence or malfunction of clotting factor IX. Treatment for Hemophilia B has historically included plasma-derived factor IX products and recombinant factor IX, aimed at replacing the deficient coagulation factor to manage and prevent bleeding episodes. Recently, the market has expanded to include longer-acting recombinant factor products, which allow for less frequent dosing and potentially improved quality of life for patients. Gene therapy has also emerged as a potential curative treatment option, with ongoing research focused on delivering a functional copy of the factor IX gene to the patient's liver cells. The Hemophilia B market is part of a specialized niche in hematology that addresses the unique needs of patients with this rare, life-long bleeding disorder through advancements in both therapeutic products and delivery methods.
Several companies actively participate in the Hemophilia B market. Pfizer and CSL Behring are established players with factor replacement therapies. Biogen has also developed long-acting clotting factor products. Moreover, uniQure and Spark Therapeutics are pioneering gene therapy approaches to provide long-term solutions for patients with Hemophilia B. These companies, along with others, contribute to the evolving landscape of therapeutic options for managing Hemophilia B, offering new hope for better hemostatic control and improved patient outcomes. Show Less Read more